Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 137

Sort by

Sort Order Select

Journal Articles

Treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma: Interim report of the Asia-Pacific multinational prospective registry study

Blood (2025) 146 (Supplement 1): 2778.

https://doi.org/10.1182/blood-2025-2778

Published: 2025

Journal Articles

Teclistamab in a large cohort of ~100 Asian patients with triple-class exposed multiple myeloma: Experience from trials and non-trial settings

Blood (2025) 146 (Supplement 1): 5815.

https://doi.org/10.1182/blood-2025-5815

Published: 2025

Journal Articles

Comparative analysis of consolidation strategies after induction chemotherapy in primary central nervous system lymphoma

Yuna Lee, Hyungwoo Cho, Jaewon Hyung, In Hye Song, Heounjeong Go, Ji Eun Park, Ho Sung Kim, Minyoung Oh, Jae Seung Kim, Jin-Sook Ryu, Sangjoon Chong, Sang Woo Song, Young-Hoon Kim, Young Hyun Cho, Seok Ho Hong, Jeong Hoon Kim, Dok Hyun Yoon

Blood (2025) 146 (Supplement 1): 5457.

https://doi.org/10.1182/blood-2025-5457

Published: 2025

Journal Articles

Clinical outcomes associated with conditioning regimens in patients with primary central nervous system lymphoma undergoing consolidation autologous stem cell transplantation

Blood (2025) 146 (Supplement 1): 5455.

https://doi.org/10.1182/blood-2025-5455

Published: 2025

Journal Articles

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study

Romain Guieze, Annamaria Frustaci, Chan Cheah, John Seymour, Dok Hyun Yoon, Irina Mocanu, Eric Mou, Pier Luigi Zinzani, Amitkumar Mehta, Constantine Tam, Judith Trotman, Yanan Zhang, Linlin Xu, Kunthel By, Amber Lussier, Shannon Fabre, Daniel Persky, Ranjana Advani

Blood (2025) 146 (Supplement 1): 3584.

https://doi.org/10.1182/blood-2025-3584

Published: 2025

Journal Articles

Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 1

Ja Min Byun, Chang-Ki Min, Kihyun Kim, Dok Hyun Yoon, Sung-Hoon Jung, Wee-Joo Chng, Chandramouli Nagarajan, Youngil Koh

Blood (2025) 146 (Supplement 1): 5835.

https://doi.org/10.1182/blood-2025-5835

Published: 2025

Journal Articles

Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO

Blood (2025) 146 (Supplement 1): 5519.

https://doi.org/10.1182/blood-2025-5519

Published: 2025

Journal Articles

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Blood (2025) 146 (Supplement 1): 5514.

https://doi.org/10.1182/blood-2025-5514

Published: 2025

Journal Articles

Phase 1 study of GCC2005, an allogeneic CD5-directed CAR-NK therapy, for patients with Relapsed/Refractory NK/T-cell malignancies

Won-Seog Kim, Dok Hyun Yoon, Youngil Koh, Seok Jin Kim, Sang Eun Yoon, Hyungwoo Cho, Jaewon Hyung, Ja Min Byun, Hyesung Jeon, Seungryel Han

Blood (2025) 146 (Supplement 1): 1043.

https://doi.org/10.1182/blood-2025-1043

Published: 2025

Journal Articles

Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups

Haifaa Abdulhaq, William Townsend, Matthew Ku, Gareth P. Gregory, Jeremy Abramson, Huiqiang Huang, Huilai Zhang, Dok Hyun Yoon, Won-Seog Kim, Herve Ghesquieres, Mark Hertzberg, Qing-Yuan Zhang, Murali Kesavan, Estefania Mulvihill, Martine Joanna Kallemeijn, Richard Ta, Voleak Choeurng, Linda Lundberg, Christopher Fox

Blood (2025) 146 (Supplement 1): 3743.

https://doi.org/10.1182/blood-2025-3743

Published: 2025

Journal Articles

Phase II study of lenalidomide in combination with rituximab, cyclophosphadmie, doxorubicin, vincristine, and prenisone (R-CHOP) for central nervous system prophylaxis in high-risk diffuse large B cell lymphoma

Hyungwoo Cho, Jaewon Hyung, Hyeon-Seok Eom, Sung-Nam Lim, Hye Jin Kang, Myung-Won Lee, Young Rok Do, Seong Hyun Jeong, Hyo Jung Kim, Youngil Koh, Seong Yoon Yi, Ka-Won Kang, Min Kyoung Kim, Jae-Yong Kwak, Gyeong-Won Lee, Dok Hyun Yoon

Blood (2025) 146 (Supplement 1): 1915.

https://doi.org/10.1182/blood-2025-1915

Published: 2025

Journal Articles

Artificial intelligence (AI)–based membrane specific PD-L1 and immune subtypes as predictive biomarkers for danburstotug in relapsed or refractory extranodal NK/T cell lymphoma (R/R ENKTL): Insights from the Phase II trial (DISTINKT)

Won Seog Kim, Seok Jin Kim, Jae-Cheol Cho, Sang Eun Yoon, Youngil Koh, Deok-Hwan Yang, Dok Hyun Yoon, Junhun Cho, Sung Young Lee, Seongyeon Kang, Woochan Hwang, Hyukjung Kim, Heung Tae Kim

Blood (2025) 146 (Supplement 1): 5426.

https://doi.org/10.1182/blood-2025-5426

Published: 2025

Journal Articles

Phase I/II study of zanubrutinib in combination with rituximab, ifosfamide, carboplatin, and etoposide (ZR-ICE) in Relapsed/Refractory diffuse large B-cell lymphoma: Results of the Phase I portion

Hyungwoo Cho, Jaewon Hyung, Dong Won Baek, Ho Sup Lee, Hye Jin Kang, Gyeong-Won Lee, Jeong-Ok Lee, Myung-Won Lee, Sung-Nam Lim, Sung Yong Oh, Ho-Jin Shin, Kwai Han Yoo, Young Rok Do, Jae-Yong Kwak, Yong-pyo Lee, Deok-Hwan Yang, Dok Hyun Yoon

Blood (2025) 146 (Supplement 1): 3702.

https://doi.org/10.1182/blood-2025-3702

Published: 2025

Journal Articles

Trial in progress: A Phase 2a Study of GI-102 (CD80/IL2v3) as a consolidation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma following anti-CD19 chimeric antigen receptor T-cell therapy (CARNATION trial)

Dok Hyun Yoon, Hyungwoo Cho, Jaewon Hyung, Yoon Seok Choi, Youngwoo Jeon, Seok Jin Kim, Youngil Koh, Nari Yun, Woohyung Lee, Chanmi Kim, Myoung Ho Jang

Blood (2025) 146 (Supplement 1): 2399.

https://doi.org/10.1182/blood-2025-2399

Published: 2025

Journal Articles

Representativeness of clone size measurement by using NGS-based immunoglobulin gene rearrangement test in comparison to flow cytometry in clonal plasma cell disorders

Hyeseong Ryu, Daehyun Chu, Jiyeon Kim, Miyoung Kim, Young-Uk Cho, Sang-Hyun Hwang, Dok Hyun Yoon, Hyungwoo Cho, Jung-Hee Lee, Seongsoo Jang

Blood (2025) 146 (Supplement 1): 5787.

https://doi.org/10.1182/blood-2025-5787

Published: 2025

Journal Articles

An open-label rollover study to assess the long-term safety of ixazomib

Sebastian Grosicki, Markus Hansson, Meletios Dimopoulos, Tadao Ishida, Vishal Kukreti, Dok Hyun Yoon, Wee-Joo Chng, Oliver Bechter, Xuejun Peng, Paul Richardson

Blood (2025) 146 (Supplement 1): 7547.

https://doi.org/10.1182/blood-2025-7547

Published: 2025

Journal Articles

Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up

Blood (2025) 146 (Supplement 1): 698.

https://doi.org/10.1182/blood-2025-698

Published: 2025

Journal Articles

Prognostic value of interim PET in patients with extranodal natural killer/T-cell lymphoma treated with non-anthracycline containing l-asparaginase based regimen

Sojin Kim, Hyungwoo Cho, Dok Hyun Yoon, Jaewon Hyung, Kyung Won Kim, Chan-sik Park, Heounjeong Go, In Hye Song, Eun Jin Chae, Yoon Se Lee, Minsu Kwon, Sang-Wook Lee, Jin-Sook Ryu

Blood (2025) 146 (Supplement 1): 3632.

https://doi.org/10.1182/blood-2025-3632

Published: 2025

Journal Articles

SOUNDTRACK-F1: A phase 3, randomized, open-label study of surovatamig (AZD0486) plus rituximab versus chemotherapy plus rituximab in patients with previously untreated follicular lymphoma

Blood (2025) 146 (Supplement 1): 3614.

https://doi.org/10.1182/blood-2025-3614

Published: 2025

Journal Articles

Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL)

Richard Miller, Ryan Wilcox, John Reneau, Costas Yannakou, Won Seog Kim, Tatyana Feldman, Youn-H Kim, Michael Khodadoust, Dejan Radeski, Robin Gasiorowski, Dok Hyun Yoon, Yuqin Song, Andrew Hotson, Suresh Mahabhashyam

Blood (2025) 146 (Supplement 1): 778.

https://doi.org/10.1182/blood-2025-778

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma: Interim report of the Asia-Pacific multinational prospective registry study

Teclistamab in a large cohort of ~100 Asian patients with triple-class exposed multiple myeloma: Experience from trials and non-trial settings

Comparative analysis of consolidation strategies after induction chemotherapy in primary central nervous system lymphoma

Clinical outcomes associated with conditioning regimens in patients with primary central nervous system lymphoma undergoing consolidation autologous stem cell transplantation

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study

Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 1

Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Phase 1 study of GCC2005, an allogeneic CD5-directed CAR-NK therapy, for patients with Relapsed/Refractory NK/T-cell malignancies

Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups

Phase II study of lenalidomide in combination with rituximab, cyclophosphadmie, doxorubicin, vincristine, and prenisone (R-CHOP) for central nervous system prophylaxis in high-risk diffuse large B cell lymphoma

Artificial intelligence (AI)–based membrane specific PD-L1 and immune subtypes as predictive biomarkers for danburstotug in relapsed or refractory extranodal NK/T cell lymphoma (R/R ENKTL): Insights from the Phase II trial (DISTINKT)

Phase I/II study of zanubrutinib in combination with rituximab, ifosfamide, carboplatin, and etoposide (ZR-ICE) in Relapsed/Refractory diffuse large B-cell lymphoma: Results of the Phase I portion

Trial in progress: A Phase 2a Study of GI-102 (CD80/IL2v3) as a consolidation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma following anti-CD19 chimeric antigen receptor T-cell therapy (CARNATION trial)

Representativeness of clone size measurement by using NGS-based immunoglobulin gene rearrangement test in comparison to flow cytometry in clonal plasma cell disorders

An open-label rollover study to assess the long-term safety of ixazomib

Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up

Prognostic value of interim PET in patients with extranodal natural killer/T-cell lymphoma treated with non-anthracycline containing l-asparaginase based regimen

SOUNDTRACK-F1: A phase 3, randomized, open-label study of surovatamig (AZD0486) plus rituximab versus chemotherapy plus rituximab in patients with previously untreated follicular lymphoma

Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only